2021
A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas.
Wang M, Hui P. A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas. Archives Of Pathology & Laboratory Medicine 2021, 145: 1367-1378. PMID: 34673912, DOI: 10.5858/arpa.2021-0098-ra.Peer-Reviewed Original ResearchBiomarkers, TumorCarcinomaDNA Copy Number VariationsDNA Polymerase IIEndometrial NeoplasmsFemaleGene DosageHumansImmunohistochemistryMicrosatellite InstabilityMolecular Diagnostic TechniquesMutationPoly-ADP-Ribose Binding ProteinsPredictive Value of TestsPrognosisTerminology as TopicTumor Suppressor Protein p53
2018
Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation
Wu X, Snir O, Rottmann D, Wong S, Buza N, Hui P. Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation. Modern Pathology 2018, 32: 650-658. PMID: 30443012, DOI: 10.1038/s41379-018-0179-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorColorectal Neoplasms, Hereditary NonpolyposisDNA-Binding ProteinsEndometrial NeoplasmsFemaleGenetic LociGenetic Predisposition to DiseaseHumansImmunohistochemistryMicrosatellite InstabilityMiddle AgedMismatch Repair Endonuclease PMS2MutL Protein Homolog 1MutS Homolog 2 ProteinPhenotypePolymerase Chain ReactionPredictive Value of TestsReproducibility of ResultsConceptsEndometrial cancerMLH1/PMS2Endometrial carcinomaMSH6 lossMicrosatellite shiftCancer cohortMismatch repair deficiency testingMicrosatellite instability-high colorectal cancerEndometrial cancer cohortLoss of PMS2Clear cell carcinomaColorectal cancer cohortHigh colorectal cancerLynch syndrome familiesMSH2/MSH6PMS2 lossCell carcinomaColorectal cancerDeficiency testingSolid malignanciesColorectal carcinomaCarcinomaCancerIsolated lossMSH-6MicroRNA signatures discriminate between uterine and ovarian serous carcinomas
Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES. MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. Human Pathology 2018, 76: 133-140. PMID: 29518404, DOI: 10.1016/j.humpath.2018.02.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCarcinomaDiagnosis, DifferentialFemaleGene Expression ProfilingGenetic Predisposition to DiseaseHumansMicroRNAsMiddle AgedNeoplasm GradingNeoplasms, Cystic, Mucinous, and SerousOligonucleotide Array Sequence AnalysisOvarian NeoplasmsPhenotypePredictive Value of TestsReproducibility of ResultsRetrospective StudiesTranscriptomeUterine NeoplasmsConceptsHigh-grade serous carcinomaOvarian serous carcinomaSerous carcinomaOvarian malignancyPrimary ovarian high-grade serous carcinomaOvarian high-grade serous carcinomaMiRNA signatureEndometrial serous carcinomaHigh-grade ovarian serous carcinomaUterine serous carcinomaEndometrial counterpartOvarian primaryTaqMan Low Density Array technologySynchronous primariesEndometrial cancerMetastatic tumorsCarcinomaPrimary siteSignature panelPathological determinationMicroRNA signatureSignificant discriminatory powerCancer cellsMalignancyLineage characteristics
2015
Diagnostic application of KRAS mutation testing in uterine microglandular proliferations
Hong W, Abi-Raad R, Alomari AK, Hui P, Buza N. Diagnostic application of KRAS mutation testing in uterine microglandular proliferations. Human Pathology 2015, 46: 1000-1005. PMID: 25997988, DOI: 10.1016/j.humpath.2015.03.010.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overBiopsyCell ProliferationCervix UteriDiagnosis, DifferentialDNA Mutational AnalysisEndometrial HyperplasiaEndometrial NeoplasmsFemaleHumansMiddle AgedMutationPredictive Value of TestsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsConceptsKRAS mutation analysisEndometrial adenocarcinomaMicroglandular hyperplasiaMicroglandular patternKRAS mutationsCareful morphological assessmentEndometrial mucinous carcinomaKRAS mutation testingCases of EMAMutation analysisFrequent KRAS mutationsElectronic medical recordsDifferential diagnostic toolHigh mitotic activityEndometrial biopsyImmunohistochemical workupUterine cervixMucinous carcinomaClinical historyDiagnostic challengeDiagnostic dilemmaGlandular proliferationMucinous lesionsMedical recordsEAC cases
2013
Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y, Wu BQ, Zhong HH, Hui P, Fang WG. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing. International Journal Of Clinical And Experimental Pathology 2013, 6: 1880-9. PMID: 24040454, PMCID: PMC3759496.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overBiopsyCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDNA Mutational AnalysisErbB ReceptorsExonsFemaleGene FrequencyGenetic Predisposition to DiseaseGenetic TestingHumansLung NeoplasmsMaleMiddle AgedMutationParaffin EmbeddingPhenotypePolymerase Chain ReactionPrecision MedicinePredictive Value of TestsPressurePrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsTissue FixationYoung AdultConceptsNon-small cell lung carcinomaCore needle biopsyCell lung carcinomaKRAS mutationsNSCLC patientsSurgical resectionEGFR mutationsLung carcinomaNeedle biopsyKRAS mutation analysisTyrosine kinase inhibitorsKRAS gene mutationsDirect sequencingMutation analysisFemale patientsAdenocarcinoma componentLung cancerPatientsEGFRExon 19Kinase inhibitorsExon 18Gene mutationsStatistical significanceResectionCancerous ‘floater’: a lesson learned about tissue identity testing, endometrial cancer and microsatellite instability
Bossuyt V, Buza N, Ngo NT, Much MA, Asis MC, Schwartz PE, Hui P. Cancerous ‘floater’: a lesson learned about tissue identity testing, endometrial cancer and microsatellite instability. Modern Pathology 2013, 26: 1264-1269. PMID: 23558568, DOI: 10.1038/modpathol.2013.63.Peer-Reviewed Original ResearchConceptsEndometrial curettageBackground endometriumStaging surgeryEndometrial cancerEndometrial polypsEndometrioid adenocarcinomaEndometrial adenocarcinomaFurther workupPap smearSecretory endometriumDiagnostic workupEndometrial cellsDNA genotypingAdenocarcinoma tissuesMolecular testingMicrosatellite instabilityAllelic patternsAdenocarcinomaPatientsConfirmation of contaminationTissue fragmentsCurettageEndometriumWorkupMolecular pathologists
2012
Comparing Two Methods of Detection for Chlamydia trachomatis in Liquid-Based Papanicolaou Tests
Levi AW, Beckman D, Hui P, Schofield K, Harigopal M, Chhieng DC. Comparing Two Methods of Detection for Chlamydia trachomatis in Liquid-Based Papanicolaou Tests. American Journal Of Clinical Pathology 2012, 138: 236-240. PMID: 22904135, DOI: 10.1309/ajcp2b7xqtcnamjp.Peer-Reviewed Original ResearchConceptsHC2 assayBD Viper SystemXTR TechnologyPositive predictive valueDNA assaysLiquid-based Papanicolaou testsNucleic acidsC trachomatisChlamydia trachomatisPredictive valueHybrid Capture 2Reverse transcriptase-polymerase chain reactionChlamydia trachomatis testingTranscriptase-polymerase chain reactionViper SystemComparable specificityCapture 2Papanicolaou testChlamydial infectionCytology samplesMethod of detectionThinPrep specimensTrachomatisAssaysSensitivity rate
2011
BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance
Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C. BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance. Acta Cytologica 2011, 55: 570-575. PMID: 22156468, DOI: 10.1159/000333274.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiopsy, Fine-NeedleCarcinomaCarcinoma, PapillaryCell Transformation, NeoplasticDNA Mutational AnalysisFemaleHumansMaleMiddle AgedPractice Guidelines as TopicPredictive Value of TestsPrognosisProto-Oncogene Proteins B-rafRiskTerminology as TopicThyroid Cancer, PapillaryThyroid GlandThyroid NeoplasmsThyroid NoduleConceptsPapillary thyroid carcinomaBRAF mutation analysisBRAF mutationsUndetermined significanceFollicular lesionsUndetermined significance/follicular lesionFine needle aspiration cytology specimensAUS/FLUS categoryMutation analysisBRAF-positive casesIndeterminate thyroid FNAsAspiration cytology specimensRisk of malignancySurgical pathology outcomeFine-needle aspiration specimensBRAF mutation testingNegative predictive valueSurgical pathology reportsThyroid follicular lesionsPredictability of malignancyThyroid fine-needle aspiration specimensSurgical interventionFinal diagnosisPathology outcomesPathology reportsComparison of Affirm VPIII and Papanicolaou Tests in the Detection of Infectious Vaginitis
Levi AW, Harigopal M, Hui P, Schofield K, Chhieng DC. Comparison of Affirm VPIII and Papanicolaou Tests in the Detection of Infectious Vaginitis. American Journal Of Clinical Pathology 2011, 135: 442-447. PMID: 21350100, DOI: 10.1309/ajcp7tbn5vzuglzu.Peer-Reviewed Original ResearchConceptsAffirm VPIIIPap testPapanicolaou testRoutine Pap testRoutine Papanicolaou testCandida speciesSensitive diagnostic testInfectious vaginitisLarge academic institutionPatient populationTrichomonas infectionBacterial vaginosisCandida vaginitisG vaginalisT vaginalisStudy populationHigh incidenceDiagnostic testsMolecular testsPatientsVaginitisVaginalisMorphologic identificationVaginosisCandidiasis
2010
Expression of glypican 3 in placental site trophoblastic tumor
Ou-Yang RJ, Hui P, Yang XJ, Zynger DL. Expression of glypican 3 in placental site trophoblastic tumor. Diagnostic Pathology 2010, 5: 64. PMID: 20868507, PMCID: PMC2954974, DOI: 10.1186/1746-1596-5-64.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorFemaleGlypicansHumansImmunohistochemistryPredictive Value of TestsPregnancyPrognosisTrophoblastic Tumor, Placental SiteUterine NeoplasmsConceptsPlacental site trophoblastic tumorPlacental site noduleInvasive cervical squamous cell carcinomaCervical squamous cell carcinomaNon-trophoblastic tumorsSquamous cell carcinomaTrophoblastic tumorCell carcinomaCytoplasmic stainingRare gestational trophoblastic neoplasmDiagnostic markerGestational trophoblastic neoplasmsGestational trophoblastic diseaseUseful diagnostic markerNon-neoplastic tissuesMembrane-bound heparan sulfate proteoglycanEndometrial adenocarcinomaUterine tumorsIntermediate trophoblastTrophoblastic diseaseTrophoblastic neoplasmsImmunohistochemical expressionHepatocellular carcinomaImmunohistochemical markersResultsEighty percent